Nanoform Finland Plc, announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects aiming to enhance nasal drug delivery to the brain of Herantis' CDNF therapies for Parkinson's disease using Nanoform's proprietary biological nanoparticle technology. Nanoform has by this Agreement achieved its near-term business target of First Biologics PoC project signed in 2021.